vs
Apellis Pharmaceuticals, Inc.（APLS）与Palomar Holdings, Inc.（PLMR）财务数据对比。点击上方公司名可切换其他公司
Palomar Holdings, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.3倍（$253.4M vs $199.9M），Palomar Holdings, Inc.同比增速更快（62.7% vs -5.9%），Palomar Holdings, Inc.自由现金流更多（$409.0M vs $-14.3M），过去两年Palomar Holdings, Inc.的营收复合增速更高（46.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Palomar Holdings, Inc.是一家专业保险控股企业，主要为存在巨灾风险敞口的住宅及商业资产提供财产保险产品，业务范围覆盖美国全境，核心业务板块包含地震、洪水、风暴等高危财产保障服务。
APLS vs PLMR — 直观对比
营收规模更大
PLMR
是对方的1.3倍
$199.9M
营收增速更快
PLMR
高出68.6%
-5.9%
自由现金流更多
PLMR
多$423.3M
$-14.3M
两年增速更快
PLMR
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $253.4M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 28.7% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 62.7% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $2.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPLMR
| Q4 25 | $199.9M | $253.4M | ||
| Q3 25 | $458.6M | $244.7M | ||
| Q2 25 | $178.5M | $203.3M | ||
| Q1 25 | $166.8M | $174.6M | ||
| Q4 24 | $212.5M | $155.8M | ||
| Q3 24 | $196.8M | $148.5M | ||
| Q2 24 | $199.7M | $131.1M | ||
| Q1 24 | $172.3M | $118.5M |
净利润APLSPLMR
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $51.5M | ||
| Q2 25 | $-42.2M | $46.5M | ||
| Q1 25 | $-92.2M | $42.9M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $30.5M | ||
| Q2 24 | $-37.7M | $25.7M | ||
| Q1 24 | $-66.4M | $26.4M |
营业利润率APLSPLMR
| Q4 25 | -25.6% | 28.7% | ||
| Q3 25 | 48.7% | 27.4% | ||
| Q2 25 | -18.6% | 29.5% | ||
| Q1 25 | -50.0% | 30.8% | ||
| Q4 24 | -12.3% | 28.9% | ||
| Q3 24 | -24.0% | 25.9% | ||
| Q2 24 | -14.7% | 25.5% | ||
| Q1 24 | -36.0% | 29.0% |
净利率APLSPLMR
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 21.0% | ||
| Q2 25 | -23.6% | 22.9% | ||
| Q1 25 | -55.3% | 24.6% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 20.5% | ||
| Q2 24 | -18.9% | 19.6% | ||
| Q1 24 | -38.5% | 22.3% |
每股收益（稀释后）APLSPLMR
| Q4 25 | $-0.40 | $2.05 | ||
| Q3 25 | $1.67 | $1.87 | ||
| Q2 25 | $-0.33 | $1.68 | ||
| Q1 25 | $-0.74 | $1.57 | ||
| Q4 24 | $-0.30 | $1.29 | ||
| Q3 24 | $-0.46 | $1.15 | ||
| Q2 24 | $-0.30 | $1.00 | ||
| Q1 24 | $-0.54 | $1.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $106.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $942.7M |
| 总资产 | $1.1B | $3.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSPLMR
| Q4 25 | $466.2M | $106.9M | ||
| Q3 25 | $479.2M | $111.7M | ||
| Q2 25 | $370.0M | $81.3M | ||
| Q1 25 | $358.4M | $119.3M | ||
| Q4 24 | $411.3M | $80.4M | ||
| Q3 24 | $396.9M | $86.5M | ||
| Q2 24 | $360.1M | $47.8M | ||
| Q1 24 | $325.9M | $61.4M |
总债务APLSPLMR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSPLMR
| Q4 25 | $370.1M | $942.7M | ||
| Q3 25 | $401.2M | $878.1M | ||
| Q2 25 | $156.3M | $847.2M | ||
| Q1 25 | $164.2M | $790.4M | ||
| Q4 24 | $228.5M | $729.0M | ||
| Q3 24 | $237.1M | $703.3M | ||
| Q2 24 | $264.3M | $532.6M | ||
| Q1 24 | $266.7M | $501.7M |
总资产APLSPLMR
| Q4 25 | $1.1B | $3.1B | ||
| Q3 25 | $1.1B | $2.9B | ||
| Q2 25 | $821.4M | $2.8B | ||
| Q1 25 | $807.3M | $2.4B | ||
| Q4 24 | $885.1M | $2.3B | ||
| Q3 24 | $901.9M | $2.3B | ||
| Q2 24 | $904.5M | $2.0B | ||
| Q1 24 | $831.9M | $1.9B |
负债/权益比APLSPLMR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $409.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $409.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 161.4% |
| 资本支出强度资本支出/营收 | 0.1% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $700.6M |
8季度趋势，按日历期对齐
经营现金流APLSPLMR
| Q4 25 | $-14.2M | $409.1M | ||
| Q3 25 | $108.5M | $83.6M | ||
| Q2 25 | $4.4M | $120.9M | ||
| Q1 25 | $-53.4M | $87.2M | ||
| Q4 24 | $19.4M | $261.2M | ||
| Q3 24 | $34.1M | $100.3M | ||
| Q2 24 | $-8.3M | $55.1M | ||
| Q1 24 | $-133.0M | $33.1M |
自由现金流APLSPLMR
| Q4 25 | $-14.3M | $409.0M | ||
| Q3 25 | $108.3M | $83.6M | ||
| Q2 25 | $4.4M | $120.8M | ||
| Q1 25 | $-53.4M | $87.1M | ||
| Q4 24 | $19.3M | $260.9M | ||
| Q3 24 | — | $100.1M | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSPLMR
| Q4 25 | -7.1% | 161.4% | ||
| Q3 25 | 23.6% | 34.2% | ||
| Q2 25 | 2.5% | 59.4% | ||
| Q1 25 | -32.0% | 49.9% | ||
| Q4 24 | 9.1% | 167.5% | ||
| Q3 24 | — | 67.4% | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSPLMR
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.2% | 0.0% |
现金转化率APLSPLMR
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 1.63× | ||
| Q2 25 | — | 2.60× | ||
| Q1 25 | — | 2.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.29× | ||
| Q2 24 | — | 2.14× | ||
| Q1 24 | — | 1.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PLMR
暂无分部数据
